Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical announces positive outcomes from landmark RESTORE clinical trial of ReActiv8®

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Sensorion reports new positive clinical results presented at the World Congress of Audiology

F2G announces $100 million financing to advance late-stage development and commercialization of novel antifungal drug candidate Olorofim in the US

Crossover

Abivax

Amolyt Pharma

Artios Pharma

Calliditas

GenSight Biologics 

Inventiva 

MD Start

LimFlow

Capital

Mainstay Medical

MaxCyte

Redx Pharma

Sensorion 

Sphere Fluidics

Industrial Biotech

Synthace

Verona Pharma

Our late-stage strategy

The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

Kinam Hong

Cedric Moreau

Joe Anderson

Jacques Theurillat

Joe is a Partner in the Sofinnova Crossover Strategy. He joined us in 2020 from Arix Bioscience plc, an LSE-listed venture capital firm where he was co-founder and CEO for 5 years.

Joe has extensive experience in the healthcare and life science industries, including 12 years as partner at Abingworth LLP, where he led venture-style investments in public companies and the formation of the firm’s public equities fund.

As an investor and active board member, he focuses on growth-stage life science companies. He has helped companies with financings, IPOs, and M&A, including Algeta (sold to Bayer for $2.9 billion), Amarin (listed on the Nasdaq), Autolus (listed on the Nasdaq) and Cytos (merged with Kuros).

Joe is upbeat about the rate of progress in life sciences. "Rapid advances in science over the past decade enabled the development of a vaccine for Covid a year after the first cases emerged. There’s no way you could have done that 10 years ago,” he said. “That’s just the tip of the iceberg. We are also seeing huge acceleration in our understanding of disease processes in cancer, cardiovascular and neurology. This pace of discovery promises to bring unprecedented benefits to human health in coming years. It is exciting to help companies find that next gear of growth as they bring new medicines to market.”

He started his career at the Wellcome Trust and became head of the strategy group for 9 years. He then moved into equities research as a pharmaceuticals analyst at Dresdner Kleinwort Benson, and then held a fund management role within First State Investments’ global healthcare & biotechnology fund, before moving into venture capital in 2004.

Kinam is a Partner with the Sofinnova Crossover Strategy. He joined us in January 2017.

Prior to joining Sofinnova Partners, Kinam was a co-Manager of the Exane Equinox Fund, a global healthcare fund backing later-stage, public biotechnology companies. Before that, he spent 10 years as an investor and analyst covering the biotechnology sector, including at Citigroup Investment Research, where he specialized in small- and mid-cap biotechnology companies.

Kinam was attracted by Sofinnova Crossover's hands-on approach to later-stage investing. "It's different when you are an active investor with a larger ownership," he said. "You have the ability to make a bigger impact. Sometimes you need to be in the room.”

Prior to his investment career, Kinam worked in new product development at Sanofi, the multinational pharmaceutical company, where he held various roles in product development, business development and strategic marketing, working on infectious diseases and oncology licensing deals, and on the company’s China strategy.

Kinam is a physician and scientist, holding degrees in molecular biology/biochemistry and medicine from the University of Florida. He also holds a CFA (Chartered Financial Analyst) and MBA from INSEAD (France).

Kinam enjoys combining the medicine and investing aspects of his role, which "has the potential to make an impact on patients and makes every day interesting."

Cedric is a Partner in the Sofinnova Crossover Strategy team. He joined us in June 2018, bringing 18 years of experience in life sciences investment banking.

Cedric joined from Oddo BHF where he was Managing Director and Head of Healthcare in the corporate finance department. In 2017, Oddo BHF was the top ranked firm for European biotech equity capital market deals.

Prior to this, he was Director at Bryan Garnier & Co, where he completed several sizable cross-border transactions, including Galapagos, DBV, Ablynx, and Celyad. In total, he has managed more than €2 billion in European healthcare transactions.

Cedric brings to the Crossover team his transactional expertise in the biopharma industry, as well as an extensive network of key opinion leaders, bankers and lawyers.

Cedric was well known to the Sofinnova team before he came onboard, having executed several mandates for portfolio companies.

He said the Sofinnova Crossover team was taking a different approach compared with crossover transactions in the U.S., which typically involve investing just ahead of a company’s IPO.

"We are more like late-stage VC investors," he said. "It's really the stage of maturity of the company that is important for us. Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage of development and proof of concept," then help them get ready for what comes next — usually a listing on the Nasdaq, and/or a deal with a major pharma or healthcare company.

Before his corporate finance career, Cedric spent 10 years as a healthcare equity analyst, and was several times EXTEL top ranked (awarded for both individual and team performances) at Natixis and Fortis. He was in charge of coverage of listed biotech and pharma companies.

Cedric holds a Master’s in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and diploma from the Société Française des Analystes Financiers (SFAF).

Jacques is a Partner in the Sofinnova Crossover Strategy. He joined us in 2017, bringing his extensive experience in biopharmaceutical company operations, as well as his know-how when it comes to making private and public investments.

His experience in building a team of international investors to deploy a new strategy is also important for the Crossover team. He is expected to take positions on the boards of some of the public companies the strategy invests in.

In 2008, Jacques co-founded and managed Ares Life Sciences, a privately owned investment fund with the objective to build and manage a portfolio of companies in life sciences. Jacques built a new team of 9 professionals and invested €1.25 billion in six public and private companies including Euromedic International BV, Esaote Spa, Bronchus Technologies Inc, Santhera Pharmaceuticals, Stallergenes SA, Greer Inc. In June 2015, Stallergenes and Greer merged creating the worldwide market leader in Allergy Immunotherapy.

Jacques had previously spent almost 20 years in the Serono pharmaceutical group, where he was deputy CEO and senior executive vice president for strategic corporate development, responsible for Serono’s global strategy and in-licensing initiatives. Jacques also served as Serono’s president of European and international sales & marketing and CFO. In his various roles at Serono, Jacques was responsible for several major equity financings of the company, including the company’s$2 billion listing on the NYSE in 2000, one of the largest-ever biotech secondary offerings worldwide. Jacques was also involved in the process that led to the sale of the company to Merck KGA for 14 billion Swiss Francs.

Jacques is a Swiss barrister and holds Bachelor of Law degrees from both Madrid University and Geneva University. He also holds a Swiss Federal Diploma (Tax Expert) and has a Master’s degree in Finance.

Claire is a Senior Associate in the Sofinnova Crossover Strategy. She joined us in February 2021 as an analyst. Prior to joining Sofinnova, Claire was a Life Sciences analyst at Andera Partners, where she identified and invested in biotech and medtech companies.

Claire has a PhD in Hemato-Oncology from Paris Diderot University, which she carried out at the Institut Curie, working on elucidating signaling pathways involved in the activity of leukemic-initiating cells in T cell acute lymphoblastic leukemia (T-ALL).

She also holds an MSc from the French engineering school Agrocampus Ouest and a degree in Biopharmaceutical Management from ESCP Business School. Her research has been published in journals such as Nature Communications and Cancer Cell.

Elliott joined Sofinnova Partners as an Analyst with the Crossover Strategy team in June 2024.

Before joining Sofinnova Partners, Elliott was at LifeArc, where he worked in Technology Transfer to support the commercialization of academic research. Prior to that, he worked as an Analyst at Clarivate, where he specialized in due diligence for Hemato-Oncology projects.

Elliott is excited by “the rapid advances in our understanding of the key drivers of disease. At Sofinnova, we get to see up close the next wave of innovations and work with companies to bring these innovations to market and positively impact human health.”

Elliott has a PhD in Oncology from Barts Cancer Institute in partnership with UCB Pharma, where he specialized in metastatic ovarian cancer and focused on understanding how the tumor extracellular matrix could modulate macrophage phenotype. His research has been published in the journal Nature Communications. He also holds a Master’s in Biochemistry and a Bachelor’s degree in Biology from the University of Portsmouth.

Alexandra joined Sofinnova Partners as an Analyst in the Crossover team in April 2024. She was previously a Venture Capital Fellow at Ysios Capital.

Alexandra came on board as she enjoys “seeing science translated into innovation that changes patients' lives, which is what we do every day at Sofinnova.”

Alexandra has a PhD in vascular biology from University College London (UCL), where she worked on vascular calcification in diabetic-associated peripheral arterial disease patients. She also has a MSc in Bioengineering from Imperial College London.

TheTeam